Understanding Hypoactive Sexual Desire Disorder (HSDD)
Hypactive Sexual Desire Disorder (HSDD), characterized by a persistent lack of sexual desire that causes distress to the individual, affects up to 10% of women and 8% of men globally. This condition often has severe psychological and social impacts.
Kisspeptin and Sexual Desire
Kisspeptin is a naturally occurring hormone that stimulates the release of other reproductive hormones in the body. Recent studies from Imperial College London, funded by the National Institute for Health and Care Research (NIHR) Imperial Biomedical Research Centre (NIHR-Imperial BRC) and the Medical Research Council, suggest that this hormone could be an effective treatment for HSDD.
Proof of Concept and Initial Trials
Researchers conducted two clinical trials involving 32 pre-menopausal women and 32 men with HSDD. The subjects underwent MRI brain scans, blood tests, and behavioural assessments. It was observed that kisspeptin enhanced sexual responses and improved sexual brain processing, leading to positive effects on sexual behaviour.
Kisspeptin-based Treatments
Based on these studies’ promising results, researchers are laying the foundation for potential kisspeptin-based treatments. Dr. Alexander Comninos from the Department of Metabolism, Digestion and Reproduction at Imperial College London commented, “Our two studies provide proof-of-concept for the development of kisspeptin treatments… kisspeptin is a potentially safe and effective therapy for both women and men with distressing low sexual desire.”
The Future of Kisspeptin Therapy
The researchers are optimistic about the therapeutic potential of kisspeptin for HSDD. The next steps include larger scale studies and collaborations to develop kisspeptin as a practical treatment for psychosexual disorders in both women and men.
Trials from a Participant’s Perspective
Peter, a 44-year-old participant in the trial, shared his experience, “I noticed a difference in terms of my sexual desire… I had the best possible outcome as a result of the trial. I am really pleased to have contributed to this trial, which has been life-changing for me.”
Eve, another participant, also saw a positive change after receiving the kisspeptin infusion and is glad to have been part of the process, recognizing that it could potentially help others dealing with low libido.
In summary, kisspeptin presents a new horizon in treating low sexual desire, with promising preliminary results and potential benefits to millions of people around the world.
Original article by Maxine Myers can be found here
